Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

TerraPower Isotopes Plans Philadelphia, Pennsylvania, Manufacturing Operations

03/24/2026
Medical isotopes and nuclear technology provider TerraPower Isotopes plans to establish operations in Philadelphia, Pennsylvania. The project is expected to create 225 jobs.

The investment will include the construction of a new 250,000-square-foot radioisotope manufacturing facility, located in the Bellwether District, that will produce actinium-225 for use in the development of cancer treatments. Operations are scheduled to begin in 2029.

"TerraPower's mission is to deliver new technologies to market that can improve lives; and the work our TerraPower Isotopes team is doing shows real promise in supporting the expansion of a diverse suite of cancer treatments using nuclear medicine," said TerraPower president and CEO Chris Levesque. "This new facility will help us increase the global supply of actinium-225 and increase access for researchers and drug developers who are advancing new cancer treatments."

The project is being supported by a funding proposal from the Pennsylvania Department of Community and Economic Development (DCED) for a $7 million grant through the PA SITES (Pennsylvania Strategic Investments to Enhance Sites) Program, and a $3 million Pennsylvania First grant. The company is also eligible to apply for the Manufacturing Tax Credit program and the Qualified Manufacturing and Innovation Reinvestment Deduction program, which could provide significant tax savings.

“TerraPower Isotopes’ decision to establish a major manufacturing facility in Philadelphia will create hundreds of good-paying jobs while strengthening the Commonwealth’s robust life sciences ecosystem,” noted DCED Secretary Rick Siger. “By partnering with innovative companies and investing in strategic sites like the Bellwether District, we’re continuing to attract transformative projects that drive economic growth across Pennsylvania.”

TerraPower Isotopes, part of TerraPower, specializing in developing and supplying critical radioisotopes for healthcare and advanced industrial applications. The company leverages advanced nuclear technologies and partnerships with national labs and industry to produce isotopes through innovative reactor and accelerator-based methods.

"TerraPower Isotopes' presence in Philadelphia will strengthen a place where health, science, and technology converge to address some of the world's most pressing challenges. The city has a long history of turning ideas and discoveries into advances that accelerate progress, and TerraPower Isotopes' arrival brings new expertise and momentum to the region's dynamic research community,” added Kevin B. Mahoney, Chief Executive Officer, University of Pennsylvania Health System.

Exclusive Research